GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » Institutional Ownership

Ovoca Bio (DUB:OVXA) Institutional Ownership : 1.36% (As of Jun. 20, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ovoca Bio's institutional ownership is 1.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ovoca Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ovoca Bio's Float Percentage Of Total Shares Outstanding is 0.00%.


Ovoca Bio Institutional Ownership Historical Data

The historical data trend for Ovoca Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Institutional Ownership Chart

Ovoca Bio Historical Data

The historical data trend for Ovoca Bio can be seen below:

2016-09-30 2016-10-31 2016-12-31 2017-01-31 2017-02-28 2017-03-31 2017-04-30 2017-05-31 2017-06-30 2017-07-31
Institutional Ownership 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36

Ovoca Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Ovoca Bio (DUB:OVXA) Business Description

Traded in Other Exchanges
Address
17 Pembroke Street Upper, Dublin, IRL, D02 AT22
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio (DUB:OVXA) Headlines

No Headlines